πŸ‡ΊπŸ‡Έ FDA
Patent

US 11890285

Combination therapies

granted A61KA61K2039/505A61K31/519

Quick answer

US patent 11890285 (Combination therapies) held by Mirati Therapeutics, Inc. expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
43
CPC classes
A61K, A61K2039/505, A61K31/519, A61K39/39541, A61K39/39558